Horizon Pharma (HZNP) plunged Tuesday on news of its hostile takeover bid for Depomed (DEPO), but with HZNP stock up 160% so far this year, shareholders can afford a little pullback. HZNP has been trying to buy DEPO since March, only to be rebuffed repeatedly.